Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.46 |
| ▸ | HTR2A | P28223 | 10/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699063 | 0.95 | HTR2A (0.44) | HTR2CHTR2AGAACACNA1GCACNA1H | |
| SCHEMBL19699052 | 0.95 | HTR2A (0.44) | HTR2CHTR2AGAACACNA1GCACNA1H | |
| SCHEMBL17618428 | 0.90 | TSHR (0.46) | HTR2CHTR2ACSF1RABL1BCR | |
| SCHEMBL17618706 | 0.89 | HTR2C (0.41) | HTR2CHTR2AALDH1A1MAPT | |
| SCHEMBL19689778 | 0.89 | HTR2C (0.41) | HTR2CHTR2AALDH1A1MAPT | |
| SCHEMBL19699058 | 0.88 | USP2 (0.35) | HTR2CHTR2AMAPTUSP2 | |
| SCHEMBL17618492 | 0.88 | ABL1 (0.42) | HTR2CHTR2AABL1BCRALDH1A1 | |
| SCHEMBL19669061 | 0.88 | LIMK2 (0.36) | HTR2CHTR2AMAPTUSP2 | |
| SCHEMBL17618354 | 0.88 | HTR2C (0.48) | HTR2CHTR2ACSF1RALDH1A1 | |
| SCHEMBL17618479 | 0.88 | THRB (0.42) | HTR2CHTR2ACACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HTR2C 4651/4885HTR2A 4386/4885GAA 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.